Multiple Sclerosis in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Multiple Sclerosis market through 2034.
GlobalData estimated that the MS market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. Across the 68 markets, sales in the Multiple Sclerosis market were $32.8 billion in 2024, growing to $41.2 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 67.0% and 62.9% of 68-market sales in 2024 and 2034, respectively.
Scope
This publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for Multiple Sclerosis, covered in GlobalData’s report “Multiple Sclerosis: Seven – Market Drug Forecast and Market Analysis”, published in June 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M).
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the MS therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the MS therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Johnson & Johnson
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Co
Novartis AG
Merck KGaA
Biogen Inc
Mitsubishi Tanabe Pharma Corp
MediciNova Inc
Pfizer Inc
Banner Life Sciences LLC
AB Science SA
Immunic Inc
Sanofi
MediciNova (Europe) Ltd
TG Therapeutics Inc
Clene Nanomedicine Inc
InnoCare Pharma Ltd
Handa Pharmaceuticals Inc
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Multiple Sclerosis reports